A 45-year-old man comes to the clinic for a routine follow-up. Four weeks ago, he was diag… — USMLE Step 3

A $45$ -year-old man comes to the clinic for a routine follow-up. Four weeks ago, he was diagnosed with active pulmonary tuberculosis and started on a regimen of isoniazid, rifampin, pyrazinamide, and ethambutol. He reports excellent adherence to the medications and says his chronic cough and night sweats have completely resolved. He currently feels well and has no nausea, vomiting, abdominal pain, fatigue, or dark urine. Vital signs are within normal limits. Physical examination reveals no scleral icterus, right upper quadrant tenderness, or hepatomegaly.

Laboratory studies show:

Test	Result	Reference Range
Total bilirubin	$0.9$ mg/dL	$0.1$ - $1.2$ mg/dL
Aspartate aminotransferase (AST)	$145$ U/L	$10$ - $40$ U/L
Alanine aminotransferase (ALT)	$152$ U/L	$7$ - $56$ U/L
Alkaline phosphatase	$90$ U/L	$44$ - $147$ U/L

Which of the following is the most appropriate next step in management?

Continue the current medication regimen and repeat liver function tests in 1 to 2 weeksAnswer
B
Discontinue all four antituberculous medications immediately until transaminases normalize
C
Admit the patient to the hospital for continuous observation and intravenous hydration
D
Order a right upper quadrant abdominal ultrasound and computed tomography of the abdomen
E
Refer the patient for a percutaneous liver biopsy to evaluate for drug-induced hepatic necrosis

Answer

Continue the current medication regimen and repeat liver function tests in 1 to 2 weeks

The correct answer is to continue the current medication regimen and repeat liver function tests in 1 to 2 weeks. Mild, asymptomatic elevation of hepatic transaminases is a well-known side effect of first-line antituberculous therapy, particularly with isoniazid, rifampin, and pyrazinamide. Clinical guidelines dictate that these hepatotoxic medications should be continued with close monitoring unless hepatic transaminases rise to greater than 5 times the upper limit of normal in an asymptomatic patient, or greater than 3 times the upper limit of normal in a symptomatic patient (e.g., presenting with nausea, vomiting, jaundice, or significant abdominal pain). In this scenario, the patient is completely asymptomatic and the AST (

145

U/L) and ALT (

152

U/L) are both well below the 5-fold threshold. Therefore, stopping or altering the therapy is not indicated, and the patient should simply undergo repeat laboratory monitoring.

Step-by-Step Solution

Evaluate the patient's clinical presentation and laboratory results.

The patient is asymptomatic (no nausea, vomiting, or jaundice) but has elevated AST (

145

U/L, < 4x ULN) and ALT (

152

U/L, < 3x ULN).

Determining the presence of symptoms and the exact degree of liver enzyme elevation is required to guide management of drug-induced liver injury.

Apply guidelines for managing hepatotoxicity during tuberculosis treatment.

Hepatotoxic drugs (isoniazid, rifampin, pyrazinamide) should only be stopped if transaminases are > 3 times the upper limit of normal in a symptomatic patient, or > 5 times the upper limit of normal in an asymptomatic patient.

Continuing therapy prevents treatment failure while safely monitoring for severe toxicity.

Select the appropriate next clinical step.

Since the transaminases are below the 5-fold threshold and the patient is completely asymptomatic, the medications should be continued and liver function tests monitored closely.

This approach aligns with standard of care for monitoring adverse effects of antituberculous therapy.

Key Concept

Asymptomatic patients taking first-line antituberculous therapy with hepatic transaminase levels less than 5 times the upper limit of normal should continue their current regimen with close clinical and laboratory monitoring.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic